How HAART Works: Targeting HIV Replication at Multiple Steps
Highly Active Antiretroviral Therapy (HAART) combines ≥3 antiretrovirals from ≥2 classes to maximally suppress HIV replication. Each class targets a distinct viral lifecycle step:
- Entry Inhibitors (maraviroc, enfuvirtide): Block CCR5 co-receptor or gp41 fusion.
- NRTIs (tenofovir, emtricitabine, abacavir): Chain-terminate reverse transcription.
- NNRTIs (efavirenz, dolutegravir, rilpivirine): Allosterically inhibit reverse transcriptase.
- Integrase Inhibitors (bictegravir, dolutegravir, raltegravir): Block viral DNA integration into host genome.
- Protease Inhibitors (darunavir, atazanavir, lopinavir): Prevent Gag-Pol polyprotein cleavage → immature, non-infectious virions.
Clinical Impact
- Sustained viral suppression (<50 copies/mL) → immune recovery (CD4↑)
- Prevents AIDS-defining illnesses, reduces transmission (U=U)
- Requires lifelong adherence; resistance emerges with interruptions
- Monitoring: viral load q3–6mo, resistance testing at failure
HAART transforms HIV into a manageable chronic condition but is not curative.
HIV & AIDS - Related Articles
- Understanding an HIV-Positive Test Result: What It Means
- Foreskin Variation: Normal Anatomy, Not Race-Based
- HIV and Vision Loss: CMV Retinitis Risk & Prevention
- AIDS and Immune System Collapse: Opportunistic Infections, Cancers, and Systemic Effects
- HIV and Casual Contact: Debunking Transmission Myths
- Understanding HIV, AIDS, and Immunodeficiency: What You Need to Know
- ICD-10 Code I33.9: Bacterial Endocarditis in AIDS — Coding Clarification
